Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
- 28 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 59 (12), 1657-1665
- https://doi.org/10.1093/cid/ciu696
Abstract
Background. Virologic failure following treatment of hepatitis C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence of resistant variants. MK-5172 is an investigational once-daily protease inhibitor. We analyzed variants in treatment-naive noncirrhotic patients with virologic failure on MK-5172 (100–800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2 trial.Keywords
This publication has 24 references indexed in Scilit:
- A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatmentJournal of Hepatology, 2013
- Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation RatePLoS Pathogens, 2012
- Resistance-Associated Variants in Chronic Hepatitis C Patients Treated with Protease InhibitorsCurrent Gastroenterology Reports, 2011
- NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1–5Antiviral Therapy, 2011
- Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus InfectionThe New England Journal of Medicine, 2011
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2011
- Telaprevir for Retreatment of HCV InfectionThe New England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007